TY  - BOOK
AU  - Kirkham,Bruce
TI  - The handbook of biological therapy: a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology 
SN  - 9780191548970
AV  - QH345 .H348 2008eb
U1  - 615.7 22
PY  - 2008///
CY  - Oxford
PB  - Oxford University Press
KW  - Biological products
KW  - Therapeutic use
KW  - Tumor necrosis factor
KW  - Inhibitors
KW  - Tumor Necrosis Factor-alpha
KW  - therapeutic use
KW  - Gastrointestinal Diseases
KW  - therapy
KW  - Rheumatic Diseases
KW  - Skin Diseases
KW  - Biological Therapy
KW  - Biothérapie
KW  - Tractus gastro-intestinal
KW  - Maladies
KW  - Traitement
KW  - MEDICAL
KW  - Pharmacology
KW  - bisacsh
KW  - fast
KW  - Electronic books
N1  - Includes bibliographical references and index; Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation; RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis; Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V; Electronic reproduction; [Place of publication not identified]; HathiTrust Digital Library; 2010
N2  - Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497
ER  -